Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published 8 August 2008 Volume 2008:4(4) Pages 821—826

DOI https://doi.org/10.2147/TCRM.S3075

Review by Single-blind

Peer reviewer comments 3

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Allergenicity and toxicology of inhaled silver nanoparticles in allergen-provocation mice models

Chuang HC, Hsiao TC, Wu CK, Chang HH, Lee CH, Chang CC, Cheng TJ

International Journal of Nanomedicine 2013, 8:4495-4506

Published Date: 22 November 2013

Titanate nanowire scaffolds decorated with anatase nanocrystals show good protein adsorption and low cell adhesion capacity

Ding XL, Yang XQ, Zhou L, Lu HB, Li SB, Gao Y, Lai CH, Jiang Y

International Journal of Nanomedicine 2013, 8:569-579

Published Date: 7 February 2013

Troponin elevation in conditions other than acute coronary syndromes

Tanindi A, Cemri M

Vascular Health and Risk Management 2011, 7:597-603

Published Date: 22 September 2011

Erratum

Xiao N, Shi S, Zhuang H

Hepatic Medicine: Evidence and Research 2011, 3:19-20

Published Date: 18 March 2011

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension

Peter Bramlage

Vascular Health and Risk Management 2009, 5:213-224

Published Date: 11 February 2009

Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease

Gjumrakch Aliev, Eldar Gasimov, Mark E Obrenovich, Kathryn Fischbach, Justin C Shenk, et al

Vascular Health and Risk Management 2008, 4:721-730

Published Date: 6 June 2008

Developments in the management of autosomal dominant polycystic kidney disease

Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Therapeutics and Clinical Risk Management 2008, 4:393-407

Published Date: 11 April 2008

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis

Michael T Nurmohamed

Vascular Health and Risk Management 2007, 3:845-852

Published Date: 15 January 2008